Evidence map›Paper›PMID 38733433›Full record

ArticleMolecular diversity2025

Design, synthesis and biological evaluation of 5H-[1,2,4]triazino[5,6-b]indole derivatives bearing a pyridinocycloalkyl moiety as iron chelators.

He Li, Yali Gao, Xin Ni, Yizu Xiong, Peixi Zhang, Han Liu, Xingye Wu, Dandan Tong, Cuifang Wang, Junjie Ma

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

He Li *School of Medicine, Huaqiao University, Quanzhou, 362000, Fujian Province, China.
Yali Gao *Pharmacy Department, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
Xin NiSchool of Medicine, Huaqiao University, Quanzhou, 362000, Fujian Province, China.
Yizu XiongSchool of Medicine, Huaqiao University, Quanzhou, 362000, Fujian Province, China.
Peixi ZhangSchool of Medicine, Huaqiao University, Quanzhou, 362000, Fujian Province, China.
Han LiuSchool of Medicine, Huaqiao University, Quanzhou, 362000, Fujian Province, China.
Xingye WuSchool of Medicine, Huaqiao University, Quanzhou, 362000, Fujian Province, China.
Dandan TongSchool of Medicine, Huaqiao University, Quanzhou, 362000, Fujian Province, China.
Cuifang WangCollege of Oceanology and Food Science, Quanzhou Normal University, Quanzhou, 362000, China. wlycf@163.com.
Junjie MaSchool of Medicine, Huaqiao University, Quanzhou, 362000, Fujian Province, China. majunjie3612@hqu.edu.cn.

Funding

Fujian Province Natural Science Foundation 2021J01309Fujian Provincial Health Technology Project 2020QNA060Quanzhou City Science and Technology Program 2022NS007the Startup Fund for scientific research, Huaqiao University 20BS113
6 · The paper itself

Abstract

The avidity of cancer cells for iron highlights the potential for iron chelators to be used in cancer therapy. Herein, we designed and synthesized a novel series of 5H-[1,2,4]triazino[5,6-b]indole derivatives bearing a pyridinocycloalkyl moiety using a ring-fusion strategy based on the structure of an iron chelator, VLX600. The antiproliferative activity evaluation against cancer cells and normal cells led to the identification of compound 3k, which displayed the strongest antiproliferative activity in vitro against A549, MCF-7, Hela and HepG-2 with IC

Indexed as

Antineoplastic AgentsDrug DesignIndolesIron Chelating AgentsApoptosisCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHEK293 CellsHumansIronStructure-Activity RelationshipAntineoplastic AgentsIndolesIronIron Chelating AgentsAnticancer activityApoptosisCell cycleIndoleIron chelatorMitochondrial pathwayVLX600 derivatives

Identifiers

PMID38733433

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.